On March 18, 2026 Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported an oral presentation and multiple poster presentations of five abstracts at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22 in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Title: Preclinical assessment of BT5528 anti-tumor activity in cell-line-derived xenograft (CDX) models of head and neck squamous cell carcinoma (HNSCC)
Type: Oral Presentation
Session: Advanced Antibody, Conjugate, and Targeted Therapeutic Platforms
Date and Time: Sunday, April 19, 4:05-4:20 p.m. PT
Abstract Number: 1325
Lead Author: Lukas Stanczuk, Ph.D., Bicycle Therapeutics
Title: EphA2 expression across molecular and histological subtypes in muscle-invasive bladder cancer (MIBC) and its association with Nectin-4 and HER2
Type: Poster Presentation
Session: Clinical Research 1
Date and Time: Sunday, April 19, 2-5 p.m. PT
Abstract Number: LB012
Lead Author: Markus Eckstein, M.D., University Hospital Erlangen (FAU Erlangen -Nürnberg)
Title: An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: results from a Phase 1/2 study
Type: Poster Presentation
Session: First-in-Human Phase I Clinical Trials
Date and Time: Monday, April 20, 9 a.m.-12 p.m. PT
Abstract Number: CT063
Lead Author: Babar Bashir, M.D., Thomas Jefferson University
Title: Preclinical assessment of BT5528 anti-tumor activity in patient-derived xenograft (PDX) models of pancreatic ductal adenocarcinoma (PDAC)
Type: Poster Presentation
Session: Hematologic Malignancies and Novel Therapeutic Modalities
Date and Time: Tuesday, April 21, 9 a.m.-12 p.m. PT
Abstract Number: 4518
Lead Author: Lukas Stanczuk, Ph.D., Bicycle Therapeutics
Title: Development and first clinical experiences of a phage display derived bicyclic peptide for EphA2-specific PET imaging
Type: Poster Presentation
Session: Diagnostic Biomarkers 2
Date and Time: Tuesday, April 21, 2-5 p.m. PT
Abstract Number: 6520
Lead Author: Ann-Christin Eder, Ph.D., University of Freiberg and German Cancer Consortium (DKTK)
The presentations will be made available in the Publications section of the Bicycle Therapeutics website at the beginning of the poster session.
(Press release, Bicycle Therapeutics, MAR 18, 2026, View Source [SID1234663696])